Retatrutide vs Pramlintide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Retatrutide

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.

Full details →

Pramlintide

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

Full details →

Side-by-Side Comparison

AspectRetatrutidePramlintide
MechanismTriple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.
Typical DosageClinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.
AdministrationSubcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.
Side EffectsSimilar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.
Best For

What They Have in Common

Both Retatrutide and Pramlintide are commonly used for:

Ready to Learn More?